135 related articles for article (PubMed ID: 29182642)
21. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
22. [Clinical studies using measurement of N-telopeptides of type 1 collagen (NTx) in patients with bone metastasis--comparison with bone scintigraphy and other metabolic bone markers].
Yamamoto I; Morita R; Konishi J; Shigeno C; Ikekubo K; Hino M; Sone T; Fujimoto R
Kaku Igaku; 1995 May; 32(5):501-10. PubMed ID: 7596071
[TBL] [Abstract][Full Text] [Related]
23. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A
J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
25. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
26. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?--a meta-analysis.
Liu T; Xu JY; Xu W; Bai YR; Yan WL; Yang HL
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):350-8. PubMed ID: 21094027
[TBL] [Abstract][Full Text] [Related]
27. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
28. Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer.
Kong QQ; Sun TW; Dou QY; Li F; Tang Q; Pei FX; Tu CQ; Chen ZQ
Int J Biol Markers; 2007; 22(3):214-20. PubMed ID: 17922466
[TBL] [Abstract][Full Text] [Related]
29. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
30. [Detection of bone metastasis by serial measurement of C-terminal telopeptide of type I collagen in patients with malignancy].
Yamamoto I; Miura H; Kigami Y; Yamamura Y; Ohta T; Yuu I; Yamamoto Y; Morita R
Kaku Igaku; 1996 Apr; 33(4):423-9. PubMed ID: 8683882
[TBL] [Abstract][Full Text] [Related]
31. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
32. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M
Respirology; 2005 Jun; 10(3):300-4. PubMed ID: 15955141
[TBL] [Abstract][Full Text] [Related]
33. [Diagnostic value of urinary N-telopeptide of type I collagen in prostate cancer: comparison with bone scintigraphy].
Fukumitsu N; Uchiyama M; Mori Y; Yanada S; Hatano T; Igarashi H; Nakada J
Kaku Igaku; 1999 May; 36(4):333-9. PubMed ID: 10390956
[TBL] [Abstract][Full Text] [Related]
34. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
35. Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis.
Washam CL; Byrum SD; Leitzel K; Ali SM; Tackett AJ; Gaddy D; Sundermann SE; Lipton A; Suva LJ
Cancer Epidemiol Biomarkers Prev; 2013 May; 22(5):972-83. PubMed ID: 23462923
[TBL] [Abstract][Full Text] [Related]
36.
Li L; Shen X; Liang Y; Li B; Si Y; Ma R
Heliyon; 2023 May; 9(5):e15980. PubMed ID: 37215848
[TBL] [Abstract][Full Text] [Related]
37. Serum Levels of NTx and TRACP5b in Giant Cell Tumor of Bone and its Clinical Implications.
Chen J; Younusi A; Cao L; Xu L; Zhou Y; Zhen T; Song X
Clin Lab; 2015; 61(8):1077-81. PubMed ID: 26427154
[TBL] [Abstract][Full Text] [Related]
38. Serum cross-linked n-telopeptides of type 1 collagen (NTx) in patients with solid tumors.
Jablonka F; Schindler F; Lajolo PP; Pinczowski H; Fonseca FL; Barbieri A; Massonetto LH; Katto FT; Del Giglio A
Sao Paulo Med J; 2009 Jan; 127(1):19-22. PubMed ID: 19466290
[TBL] [Abstract][Full Text] [Related]
39. N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases.
Kaira R; Murakami H; Kaira K; Takahashi T; Tsuya A; Nakamura Y; Naito T; Endo M; Yamamoto N
Int J Clin Oncol; 2010 Oct; 15(5):484-8. PubMed ID: 20556457
[TBL] [Abstract][Full Text] [Related]
40. ICTP in bone metastases of lung cancer.
Franjević A; Pavićević R; Bubanović G
Coll Antropol; 2011 Mar; 35(1):43-7. PubMed ID: 21661353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
